Aqua Pharmaceuticals, a specialty pharmaceutical company, acquires, develops and markets drugs indicated for the treatment of dermatological conditions. The company has leading branded prescription drugs in four therapeutic categories that include acne, steroid-responsive dermatoses, actinic keratoses and seborrheic dermatitis.
An essential element in Aqua's strategy for strong, sustainable growth is to build beyond the current product portfolio by developing, licensing and acquiring products for treating skin conditions. Importantly, Aqua looks to expand its opportunities through product development, in-licensing, co-promotion, product or company acquisition and partnerships. These deals are expected to leverage the capabilities of the company's expertise and its financials.
Recently, in June 2010, RoundTable Healthcare Partners made a controlling investment in Aqua and will work closely with Aqua's Management team to expand upon the company's current product portfolio through an active program of acquisition, licensing and internal drug development. RoundTable's investment strategy targets companies in the healthcare industry that fall within the expertise and experience of the firm's operating and transaction principals. RoundTable has established a successful track record of working with owner/founders, family companies, management teams, entrepreneurs and corporate partners who share a vision and believe in the value creation potential of its partnership model. RoundTable currently manages $1.9 billion in capital, including three equity funds totaling $1.5 billion and two subordinated debt funds totaling $400 million. More information about RoundTable Healthcare Partners can be found at www.roundtablehp.com.
If you have interest in discussing corporate and business development opportunities that you believe may be of interest to Aqua, please submit the Business Opportunity Inquiry form at right or contact us:
158 West Gay Street, Suite 310
West Chester, PA 19380
Business Opportunity Inquiry
Required fields are marked with *